Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy
- Substances:AnastrozoleCamizestrant+6
Portugal- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:AstraZeneca AB
Rare diseases
Investigational molecules
Locations
Back to Portugal30 clinical trials in Amadora, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
PortugalThe busiest research cities in the country
What the registry says about research in the country
Innovative trials focusing on breast cancer treatments, including studies for HER2-positive and triple-negative variants. Research evaluates new therapeutic approaches for ovarian cancer and non-small cell lung cancer.
Multiple studies exploring targeted therapies and immunotherapy combinations to improve patient outcomes.
Clinical research targeting systemic lupus erythematosus and related conditions. Studies evaluate novel treatments for scleroderma-related lung disease and inflammatory conditions.
Focus on developing safer and more effective treatments for chronic autoimmune conditions.
Research examining treatments for Type 2 diabetes with cardiovascular complications. Studies investigating new approaches for stroke prevention and vascular health.
Comprehensive evaluation of therapeutic interventions for complex cardiometabolic conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.